UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Determining the biomarker landscape and its impact on outcomes in HPV+ head and neck cancer after primary resection

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e17520-e17520

2019

Volltextzugriff (PDF)

A phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS6105-TPS6105

2022

Volltextzugriff (PDF)

Brain metastases treated with immune checkpoint inhibitors: A single center experience

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e14012-e14012

2018

Volltextzugriff (PDF)

Characterizing chromosome 3p/q genes as biomarkers of treatment response in squamous cell carcinoma of the lung and head and neck

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18048-e18048

2023

Volltextzugriff (PDF)

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Journal of clinical oncology, 2023-02, Vol.41 (5), p.1132-1146

2023

Volltextzugriff (PDF)

Genomic profiling and outcomes of BRAF V600E mutated papillary thyroid cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18086-e18086

2022

Volltextzugriff (PDF)

Bone metastases treated with immune checkpoint inhibitors: A single center experience

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14105-e14105

2019

Volltextzugriff (PDF)

Preliminary effects on the innate immune system with the combination of cetuximab and durvalumab in metastatic/ relapsed head and neck squamous cell carcinoma in a phase II trial

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14273-e14273

2019

Volltextzugriff (PDF)

Tolerability and preliminary efficacy of BXQ-350 for refractory solid tumors and high-grade gliomas: First-in-human, first-in-class phase I trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3505-3505

2020

Volltextzugriff (PDF)

BXQ-350 may alleviate symptoms of chemotherapy- induced peripheral neuropathy via modulation of S1P

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.93-93

2023

Volltextzugriff (PDF)

BXQ-350: Modulating ceramide and sphingosine-1-phosphate for antitumor activity in patients with advanced CRC

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.154-154

2023

Volltextzugriff (PDF)

Bedside to benchtop translational development: Targeting the S1P/ceramide axis may alleviate symptoms of chemical induced peripheral neuropathy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e15045-e15045

2022

Volltextzugriff (PDF)

S1P/ceramides and cytokines as potential biomarkers of response following administration of bxq-350

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e15007-e15007

2022

Volltextzugriff (PDF)

A phase 1, safety and dose escalation study of BXQ-350, a nanovesicle formulation of saposin c, a modulator of sphingolipid metabolism, in patients with advanced solid malignancies

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e15059-e15059

2022

Volltextzugriff (PDF)

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9509-9509

2023

Volltextzugriff (PDF)

AST-008: A novel approach to TLR9 agonism with PD-1 blockade for anti-PD-1 refractory Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (CSCC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS3164-TPS3164

2020

Volltextzugriff (PDF)

Incidence of hypothyroidism in head and neck squamous cell carcinoma patients receiving radiotherapy with and without immune checkpoint inhibitors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e18551-e18551

2020

Volltextzugriff (PDF)

Genomic characterization of p16+ compared to p16- HNSCC patients treated with immune checkpoint inhibitors and overall survival

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e18024-e18024

2021

Volltextzugriff (PDF)

Molecular profiling and survival outcomes of p16+ compared to p16- oropharynx squamous cell cancer patients

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e18026-e18026

2021

Volltextzugriff (PDF)

Treatment outcomes of recurrent and metastatic adenoid cystic carcinoma: A retrospective analysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e18056-e18056

2021

Volltextzugriff (PDF)

Comprehensive genomic profiling and immune characterization of adenoid cystic carcinoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e18050-e18050

2021

Volltextzugriff (PDF)

Impact of metformin on survival and mTOR pathway in head and neck cancer patients: An updated analysis

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e17500-e17500

2017

Volltextzugriff (PDF)

An update on the overall epidemiology, clinical characteristics, and outcomes from the COVID-19 and Cancer Consortium (CCC19)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.10565-10565

2022

Volltextzugriff (PDF)

An open-label, multicenter, phase 1b/2 study of RP1, a first-in-class, enhanced potency oncolytic virus in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9597-TPS9597

2022

Volltextzugriff (PDF)

Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9553-9553

2022

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(46)
Dissertationen
(1)

Sprache

Englisch
(47)

Erscheinungsjahr

n.n

Thema

10 weitere anzeigen...

Weniger anzeigen...

Kollektion

4 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Determining the biomarker landscape and its impact on outcomes in HPV+ head and neck cancer after primary resection

A phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma

Brain metastases treated with immune checkpoint inhibitors: A single center experience

Characterizing chromosome 3p/q genes as biomarkers of treatment response in squamous cell carcinoma of the lung and head and neck

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Genomic profiling and outcomes of BRAF V600E mutated papillary thyroid cancer

Bone metastases treated with immune checkpoint inhibitors: A single center experience

Preliminary effects on the innate immune system with the combination of cetuximab and durvalumab in metastatic/ relapsed head and neck squamous cell carcinoma in a phase II trial

Tolerability and preliminary efficacy of BXQ-350 for refractory solid tumors and high-grade gliomas: First-in-human, first-in-class phase I trial

BXQ-350 may alleviate symptoms of chemotherapy- induced peripheral neuropathy via modulation of S1P

BXQ-350: Modulating ceramide and sphingosine-1-phosphate for antitumor activity in patients with advanced CRC

Bedside to benchtop translational development: Targeting the S1P/ceramide axis may alleviate symptoms of chemical induced peripheral neuropathy

S1P/ceramides and cytokines as potential biomarkers of response following administration of bxq-350

A phase 1, safety and dose escalation study of BXQ-350, a nanovesicle formulation of saposin c, a modulator of sphingolipid metabolism, in patients with advanced solid malignancies

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study

AST-008: A novel approach to TLR9 agonism with PD-1 blockade for anti-PD-1 refractory Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (CSCC)

Incidence of hypothyroidism in head and neck squamous cell carcinoma patients receiving radiotherapy with and without immune checkpoint inhibitors

Genomic characterization of p16+ compared to p16- HNSCC patients treated with immune checkpoint inhibitors and overall survival

Molecular profiling and survival outcomes of p16+ compared to p16- oropharynx squamous cell cancer patients

Treatment outcomes of recurrent and metastatic adenoid cystic carcinoma: A retrospective analysis

Comprehensive genomic profiling and immune characterization of adenoid cystic carcinoma

Impact of metformin on survival and mTOR pathway in head and neck cancer patients: An updated analysis

An update on the overall epidemiology, clinical characteristics, and outcomes from the COVID-19 and Cancer Consortium (CCC19)

An open-label, multicenter, phase 1b/2 study of RP1, a first-in-class, enhanced potency oncolytic virus in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)

Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE)

Suchergebnisse filtern